Vident Investment Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Vident Investment Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23,847	Closed	-$4.38M	–	1280
2021 Q2	$4.38M	Buy	23,847 +2,145	+10%	+$368K	0.13%	148
2021 Q1	$3.32M	Buy	+21,702	New	+$3.36M	0.11%	171
2020 Q4	–	Sell	-31,524	Closed	-$3.61M	–	936
2020 Q3	$3.61M	Buy	31,524 +17,596	+126%	+$1.9M	0.18%	105
2020 Q2	$1.56M	Buy	13,928 +7,296	+110%	+$775K	0.08%	293
2020 Q1	$596K	Buy	+6,632	New	+$651K	0.04%	532
2018 Q2	–	Sell	-3,780	Closed	-$416K	–	997
2018 Q1	$416K	Sell	3,780 -4,302	-53%	-$514K	0.02%	690
2017 Q4	$966K	Buy	8,082 +17	+0.2%	+$2.07K	0.04%	382
2017 Q3	$1.13M	Buy	+8,065	New	+$1.1M	0.06%	350
2015 Q3	–	Sell	-19	Closed	-$3K	–	1177
2015 Q2	$3K	Buy	+19	New	+$3.28K	﹤0.01%	1054

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Vident Investment Advisory's ALXN Position: Q3 2021 in Review

Vident Investment Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 23,847 shares — an estimated $4.38M sold.

Vident Investment Advisory first reported a position in ALXN in Q2 2015 and held it in 9 quarters. The position peaked at $4.38M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Vident Investment Advisory reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Vident Investment Advisory sold 23,847 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.38M.
Vident Investment Advisory first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Vident Investment Advisory's Alexion Pharmaceuticals position peaked at $4.38M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.